Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1968 2
1969 1
1972 1
1973 1
1978 1
1979 1
1983 2
1985 2
1988 2
1990 2
1991 3
1992 4
1993 2
1994 2
1995 1
1996 1
1997 1
1999 3
2000 3
2001 5
2002 5
2003 4
2004 6
2005 8
2006 9
2007 9
2008 8
2009 11
2010 6
2011 11
2012 13
2013 21
2014 11
2015 17
2016 26
2017 19
2018 14
2019 16
2020 27
2021 26
2022 21
2023 29
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Dabigatran versus warfarin in patients with atrial fibrillation.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Connolly SJ, et al. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717844 Free article. Clinical Trial.
The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as …
The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice …
RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rate …
[On the history of the Kursk parasitologic school].
Tkachenko PV, Nikishina NA, Belousova NI. Tkachenko PV, et al. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2023 Sep;31(5):1054-1058. doi: 10.32687/0869-866X-2023-31-5-1054-1058. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2023. PMID: 37898899 Russian.
Particular attention is paid to results of scientific research of professor N. P. Kevorkov and his disciple professor G. M. Tkachenko at the Kursk State Medical Institute. The theoretical and practical significance of the study is in restoration of contribution of N …
Particular attention is paid to results of scientific research of professor N. P. Kevorkov and his disciple professor G. M. Tkache …
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Hokusai-VTE Investigators, et al. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. N Engl J Med. 2013. PMID: 23991658 Free article. Clinical Trial.
Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noni …
Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2 …
[Neurophysiological differentiation of personality disorders].
Kirenskaya AV, Samylkin DV, Storozheva ZI, Myamlin VV, Tkachenko AA. Kirenskaya AV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(11):124-130. doi: 10.17116/jnevro2022122111124. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 36440789 Russian.
RESULTS: The decrease of PPI and P50 suppression (measures of sensorimotor and sensory gating) relative to the control group was found both for Sz (p<0.01) and PD1 (p<0.05) groups. The highest P300 amplitude was observed in the control group, while the lowest …
RESULTS: The decrease of PPI and P50 suppression (measures of sensorimotor and sensory gating) relative to the control group was found both …
Banana Peels: A Waste Treasure for Human Being.
Hikal WM, Said-Al Ahl HAH, Bratovcic A, Tkachenko KG, Sharifi-Rad J, Kačániová M, Elhourri M, Atanassova M. Hikal WM, et al. Evid Based Complement Alternat Med. 2022 May 13;2022:7616452. doi: 10.1155/2022/7616452. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35600962 Free PMC article. Review.
Vaccination with Helicobacter pylori attachment proteins protects against gastric cancer.
Bugaytsova JA, Piddubnyi A, Tkachenko I, Rakhimova L, Edlund JO, Thorell K, Marcotte H, Lundquist A, Schön K, Lycke N, Suerbaum S, Schulz C, Malfertheiner P, Hansen LM, Solnick JV, Moskalenko R, Hammarström L, Borén T. Bugaytsova JA, et al. bioRxiv [Preprint]. 2023 Jul 4:2023.05.25.542131. doi: 10.1101/2023.05.25.542131. bioRxiv. 2023. PMID: 37461695 Free PMC article. Preprint.
Inhibition of DYRK1a Enhances Cardiomyocyte Cycling After Myocardial Infarction.
Young A, Bradley LA, Farrar E, Bilcheck HO, Tkachenko S, Saucerman JJ, Bekiranov S, Wolf MJ. Young A, et al. Circ Res. 2022 Apr 29;130(9):1345-1361. doi: 10.1161/CIRCRESAHA.121.320005. Epub 2022 Apr 4. Circ Res. 2022. PMID: 35369706 Free PMC article.
Harmine also increased cardiomyocyte cycling after I/R MI in alphaDKRC::RLTG mice, 10.81.5 versus 24.32.6 enhanced Green Fluorescent Protein (eGFP)+ cardiomyocytes, placebo versus harmine, respectively, P=1.010(-)(3). The effects of harmine on left ventricular ejection fra …
Harmine also increased cardiomyocyte cycling after I/R MI in alphaDKRC::RLTG mice, 10.81.5 versus 24.32.6 enhanced Green Fluorescent Protein …
Helicobacter pylori attachment-blocking antibodies protect against duodenal ulcer disease.
Bugaytsova JA, Moonens K, Piddubnyi A, Schmidt A, Edlund JO, Lisiutin G, Brännström K, Chernov YA, Thorel K, Tkachenko I, Sharova O, Vikhrova I, Butsyk A, Shubin P, Chyzhma R, Johansson DX, Marcotte H, Sjöström R, Shevtsova A, Bylund G, Rakhimova L, Lundquist A, Berhilevych O, Kasianchuk V, Loboda A, Ivanytsia V, Hultenby K, Persson MAA, Gomes J, Matos R, Gartner F, Reis CA, Whitmire JM, Merrell DS, Pan-Hammarström Q, Landström M, Oscarson S, D'Elios MM, Agreus L, Ronkainen J, Aro P, Engstrand L, Graham DY, Kachkovska V, Mukhopadhyay A, Chaudhuri S, Karmakar BC, Paul S, Kravets O, Camorlinga M, Torres J, Berg DE, Moskalenko R, Haas R, Remaut H, Hammarström L, Borén T. Bugaytsova JA, et al. bioRxiv [Preprint]. 2023 May 24:2023.05.24.542096. doi: 10.1101/2023.05.24.542096. bioRxiv. 2023. PMID: 37292721 Free PMC article. Preprint.
340 results